Vision Outcomes for Pediatric Patients With Optic Pathway Gliomas Associated With Neurofibromatosis Type I: A Systematic Review of the Clinical Evidence
- PMID: 33480655
- DOI: 10.1097/MPH.0000000000002060
Vision Outcomes for Pediatric Patients With Optic Pathway Gliomas Associated With Neurofibromatosis Type I: A Systematic Review of the Clinical Evidence
Abstract
Children with neurofibromatosis type I (NF1) have a higher predisposition for low-grade astrocytomas of the optic pathway, commonly referred to as optic pathway gliomas (OPGs). OPGs can result in visual deterioration. Treatment outcomes in OPG-NF1 management are often reported around tumor stabilization. We sought to compare vision outcomes associated with different OPG treatment strategies to inform about this important functional metric. A meta-analysis exploring the different modalities to treat children with OPG-NF1 was conducted following Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines using multiple databases. Of the 113 articles identified in the search, 23 full text articles, representing 564 patients, were included for review. These articles included retrospective, prospective, and randomized controlled studies on observation (n=9), chemotherapy (n=19), radiation therapy (n=6), and surgery (n=7). Of the patients undergoing observation, 87% (60/69) demonstrated stable acuity. In the chemotherapy studies, 27.3% (72/264) demonstrated improved acuity/visual field and/or visual-evoked potential amplitudes, 39.4% (104/264) stable acuity, and 33.3% (88/264) deterioration. Both the radiation and surgical treatments reported worsening acuity at 90.9% (10/11) and 73.3% (11/15), respectively. Causal associations are not known. Indications for and timing of treatment choice warrant larger scale study to provide further understanding.
Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.
Conflict of interest statement
The authors declare no conflict of interest.
Similar articles
-
Optic Pathway Gliomas in Neurofibromatosis Type 1.J Child Neurol. 2018 Jan;33(1):73-81. doi: 10.1177/0883073817739509. J Child Neurol. 2018. PMID: 29246098 Free PMC article. Review.
-
Neurofibromatosis type 1-associated optic pathway gliomas: pathogenesis and emerging treatments.Eur Rev Med Pharmacol Sci. 2023 Jun;27(12):5636-5653. doi: 10.26355/eurrev_202306_32804. Eur Rev Med Pharmacol Sci. 2023. PMID: 37401302 Clinical Trial.
-
Visual outcomes following everolimus targeted therapy for neurofibromatosis type 1-associated optic pathway gliomas in children.Pediatr Blood Cancer. 2021 Apr;68(4):e28833. doi: 10.1002/pbc.28833. Epub 2020 Dec 18. Pediatr Blood Cancer. 2021. PMID: 33336845 Clinical Trial.
-
Optic Pathway Gliomas in Neurofibromatosis Type 1: An Update: Surveillance, Treatment Indications, and Biomarkers of Vision.J Neuroophthalmol. 2017 Sep;37 Suppl 1(Suppl 1):S23-S32. doi: 10.1097/WNO.0000000000000550. J Neuroophthalmol. 2017. PMID: 28806346 Free PMC article. Review.
-
Optic pathway gliomas in patients with neurofibromatosis type 1: follow-up of 44 patients.J AAPOS. 2010 Apr;14(2):155-8. doi: 10.1016/j.jaapos.2009.11.020. J AAPOS. 2010. PMID: 20451859
Cited by
-
Neurofibromatosis Type 1: Pediatric Aspects and Review of Genotype-Phenotype Correlations.Cancers (Basel). 2023 Feb 14;15(4):1217. doi: 10.3390/cancers15041217. Cancers (Basel). 2023. PMID: 36831560 Free PMC article. Review.
-
Supratentorial Pediatric Midline Tumors and Tumor-like Lesions: Clinical Spectrum, Natural History and Treatment Options.Children (Basel). 2022 Apr 9;9(4):534. doi: 10.3390/children9040534. Children (Basel). 2022. PMID: 35455578 Free PMC article. Review.
-
Visual Deficits and Diagnostic and Therapeutic Strategies for Neurofibromatosis Type 1: Bridging Science and Patient-Centered Care.Vision (Basel). 2024 May 9;8(2):31. doi: 10.3390/vision8020031. Vision (Basel). 2024. PMID: 38804352 Free PMC article. Review.
References
-
- Xu G, Lin B, Tanaka K, et al. The catalytic domain of the neurofibromatosis type 1 gene product stimulates ras GTPase and complements ira mutants of S. cerevisiae. Cell. 1990;63:835–841.
-
- Trevisson E, Cassina M, Opocher E, et al. Natural history of optic pathway gliomas in a cohort of unselected patients affected by Neurofibromatosis 1. J Neurooncol. 2017;134:279–287.
-
- Fried I, Tabori U, Tihan T, et al. Optic pathway gliomas: a review. CNS Oncol. 2013;2:143–159.
-
- Lewis RA, Gerson LP, Axelson KA, et al. von Recklinghausen Neurofibromatosis. Ophthalmology. 1984;91:929–935.
-
- Listernick R, Charrow J, Greenwald MJ, et al. Optic gliomas in children with neurofibromatosis type 1. J Pediatr. 1989;114:788–792.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous